CRVO director and 10% owner increases CervoMed stake via open buys

Q: What insider transaction did CervoMed (CRVO) report on this Form 4?

The filing reports that a director and 10% owner of CervoMed bought common stock in open‑market transactions on 11/17/2025 , including purchases in a spouse’s IRA.

Q: How many CervoMed (CRVO) shares did the insider buy in this transaction?

The reporting person bought 10,793 CervoMed common shares directly and 10,807 shares were purchased in the reporting person’s spouse’s IRA on 11/17/2025 .

Q: At what price were the CervoMed (CRVO) insider shares purchased?

Both sets of purchases used a weighted average price of $8.46 per share , with individual trades executed in ranges between $8.38 and $8.50 or between $8.39 and $8.46 , as applicable.

Q: How are the CervoMed (CRVO) insider’s holdings structured between direct and joint ownership?

The 1,484,078 directly reported shares include 1,471,578 shares held jointly with the reporting person’s spouse and 12,500 shares held by the Sylvie Gregoire Roth IRA.

Q: What do the price ranges in the CervoMed (CRVO) Form 4 mean?

The filing explains that the reported $8.46 prices are weighted averages for multiple open‑market trades executed in price ranges, and the insider offers to provide detailed trade breakdowns upon request.

Filing Impact

(Moderate)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

CervoMed Inc. (CRVO) director and 10% owner reported open‑market purchases of common stock. On 11/17/2025, the reporting person bought 10,793 shares of CervoMed common stock at a weighted average price of $8.46 per share in open‑market transactions. On the same date, an additional 10,807 shares were purchased at a weighted average price of $8.46 per share in an individual retirement account held by the reporting person’s spouse. After these transactions, the reporting person beneficially owned 1,484,078 shares directly and 12,500 shares indirectly through the spouse’s IRA, including shares jointly held with the issuer’s President & Chief Executive Officer.

Insider Trade Summary

Net Buyer: 21,600 shares ($182,736)

Net Buy 2 txns

Insider Gregoire Sylvie

Role Director, 10% Owner

Bought 21,600 shs ($183K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,793	$8.46	$91K
Purchase	Common Stock	10,807	$8.46	$91K

Holdings After Transaction: Common Stock — 1,484,078 shares (Direct); Common Stock — 12,500 shares (Indirect, Spouse's IRA)

Footnotes (1)

Shares purchased in open-market transactions. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $8.38 to $8.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. Includes (i) 1,471,578 hares held jointly by the Reporting Person and her spouse, Dr. John Alam, M.D., the Issuer's President & Chief Executive Officer and a member of the Issuer's Board of Directors and (ii) 12,500 shares held by the Sylvie Gregoire Roth IRA. Shares held by the John J. Alam Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $8.39 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

11/19/2025 - 07:45 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gregoire Sylvie

(Last)

(First)

(Middle)

20 PARK PLAZA, SUITE 424

(Street)

BOSTON

02116

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/17/2025		P		10,793⁽¹⁾	A	$8.46⁽²⁾	1,484,078⁽³⁾	D
Common Stock	11/17/2025		P		10,807⁽¹⁾⁽⁴⁾	A	$8.46⁽⁵⁾	12,500⁽⁴⁾	I	Spouse's IRA⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares purchased in open-market transactions.

2. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $8.38 to $8.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.

3. Includes (i) 1,471,578 hares held jointly by the Reporting Person and her spouse, Dr. John Alam, M.D., the Issuer's President & Chief Executive Officer and a member of the Issuer's Board of Directors and (ii) 12,500 shares held by the Sylvie Gregoire Roth IRA.

4. Shares held by the John J. Alam Roth IRA.

5. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $8.39 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CervoMed (CRVO) report on this Form 4?

The filing reports that a director and 10% owner of CervoMed bought common stock in open‑market transactions on 11/17/2025, including purchases in a spouse’s IRA.

How many CervoMed (CRVO) shares did the insider buy in this transaction?

The reporting person bought 10,793 CervoMed common shares directly and 10,807 shares were purchased in the reporting person’s spouse’s IRA on 11/17/2025.

At what price were the CervoMed (CRVO) insider shares purchased?

Both sets of purchases used a weighted average price of $8.46 per share, with individual trades executed in ranges between $8.38 and $8.50 or between $8.39 and $8.46, as applicable.

How many CervoMed (CRVO) shares does the insider own after the reported trades?

After the reported transactions, the insider beneficially owned 1,484,078 CervoMed shares directly and 12,500 shares indirectly through the spouse’s IRA.

How are the CervoMed (CRVO) insider’s holdings structured between direct and joint ownership?

The 1,484,078 directly reported shares include 1,471,578 shares held jointly with the reporting person’s spouse and 12,500 shares held by the Sylvie Gregoire Roth IRA.

What do the price ranges in the CervoMed (CRVO) Form 4 mean?

The filing explains that the reported $8.46 prices are weighted averages for multiple open‑market trades executed in price ranges, and the insider offers to provide detailed trade breakdowns upon request.